UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, DC ~~D.C.~~ 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE~~

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the ~~Month~~month of October 2025

Commission ~~file~~File ~~number~~Number 001-41291

~~Meihua~~MEIHUA ~~International~~INTERNATIONAL ~~Medical~~MEDICAL ~~Technologies~~TECHNOLOGIES CoCO., ~~Ltd~~LTD.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive ~~office~~offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~Entry into a Private Placement~~Other Events

~~Meihua~~Attached hereto ~~International~~as ~~Medical~~Exhibit 99.1 ~~Technologies~~and CoExhibit 99.~~, Ltd.~~2 ~~(the~~are ~~“Company”)~~a ~~entered~~Notice ~~into~~of ~~certain~~Extraordinary ~~securities~~General ~~purchase~~Meeting ~~agreement~~of Shareholders (the “~~SPA~~Notice”) ~~with certain “non-U.S.~~ ~~Persons”~~and ~~(the~~a ~~“Purchasers”)~~Proxy asCard, ~~defined~~respectively, ~~in Regulation S~~ of ~~the~~Meihua ~~Securities~~International ~~Act~~Medical ofTechnologies ~~1933~~Co., asLtd. ~~amended~~ (the “~~Securities Act~~Company”) onrelating ~~October 8, 2025. Pursuant~~ to the ~~SPA, the~~ Company ~~agreed to sell up to an aggregate of 40,000,000 ordinary shares of the~~’s ~~Company,~~extraordinary ~~par~~general ~~value~~meeting ~~$0.0005 per share (“Shares”), with the purchase price~~ of ~~$0.38~~shareholders ~~per Share~~ (the “~~Offering~~EGM”), ~~for gross proceeds of $15.2 million. The Company currently intends~~ to ~~use~~be ~~the~~held ~~net~~on ~~proceeds~~November ~~from~~3, ~~the Offering for working capital and general corporate purposes~~2025.

~~The parties~~ Where to ~~the~~Find ~~SPA~~Additional have each made customary representations, warranties and covenants, including, among other things, (a) the Purchasers are “non-U.S. Persons” as defined in Regulation S and are acquiring the Shares for the purpose of investment, (b) the absence of any undisclosed material adverse effect, and (c) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA.Information

The Company ~~Shares~~is ~~were~~a ~~issued~~foreign inprivate ~~reliance~~issuer. onAs such, the ~~exemption from~~Notice ~~registration~~is ~~provided~~not bysubject ~~Regulation~~to Sreview ~~under~~and comment by the Securities ~~Act~~and ofExchange ~~1933~~Commission (the “SEC”).

~~The~~Shareholders are ~~closing~~urged to carefully read the Notice, because it contains important information about the Company and the EGM. Copies of Notice and other documents filed or submitted by the ~~Offering~~Company will be ~~subject~~available to at the ~~satisfaction~~website maintained by the SEC at www.sec.gov. Shareholders may obtain a copy of ~~all~~such filings, free of charge, from the ~~closing~~Company’s ~~conditions~~website ~~set~~at ~~forth~~http://ir.meihuamed.com/ inor ~~the~~by ~~SPA~~writing to us at 88 Tongda Road, Touqiao Town, Guangling District, Yangzhou, 225000, People’s Republic of China.

~~The form of the SPA is filed as Exhibit 99.1,~~Participants ~~and~~in ~~such document is incorporated herein by reference. The foregoing is only a brief description of~~ the ~~material terms of the SPA, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit.~~Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the EGM. Information regarding certain directors and executive officers of the Company is available in the Company’s documents filed with or submitted to the SEC. Other information regarding the participants in the proxy solicitation and descriptions of their direct and indirect interests, by security holdings or otherwise, are set forth in the Notice filed herewith.

Exhibits

Exhibit No.		Description
99.1		~~Form~~Notice of ~~Securities~~Extraordinary ~~Purchase~~General ~~Agreement~~Meeting of Shareholders and Proxy Statement
99.2		Proxy Card

~~SIGNATURE~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Meihua International Medical Technologies Co., Ltd.
	MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
By:	/s/ Leyi Lee
Date: October 23, 2025	By:	/s/ Leyi Lee
~~Name:~~	~~Leyi Lee~~	Name:	Leyi Lee
~~Title:~~	~~Chief Executive Officer~~	Title:	Chief Executive Officer
Date: October 14, 2025

Filing Compare · Meihua International Medical Technologies Co., Ltd.